| Style | Citing Format |
|---|---|
| MLA | Damavandi AR, Fathi F, Eskandari N. "Response to Sriwijitalai and Wiwanitkit Re: The Association of Programmed Death 1 Gene Polymorphisms of Pd1.3 G/A and Pd1.5 C/T With Risk of Covid-19 in an Iranian Population: A Case-Control Study." Viral Immunology, vol. 35, no. 7, 2022, pp. 515-. |
| APA | Damavandi AR, Fathi F, Eskandari N (2022). Response to Sriwijitalai and Wiwanitkit Re: The Association of Programmed Death 1 Gene Polymorphisms of Pd1.3 G/A and Pd1.5 C/T With Risk of Covid-19 in an Iranian Population: A Case-Control Study. Viral Immunology, 35(7), 515-. |
| Chicago | Damavandi AR, Fathi F, Eskandari N. "Response to Sriwijitalai and Wiwanitkit Re: The Association of Programmed Death 1 Gene Polymorphisms of Pd1.3 G/A and Pd1.5 C/T With Risk of Covid-19 in an Iranian Population: A Case-Control Study." Viral Immunology 35, no. 7 (2022): 515-. |
| Harvard | Damavandi AR, Fathi F, Eskandari N (2022) 'Response to Sriwijitalai and Wiwanitkit Re: The Association of Programmed Death 1 Gene Polymorphisms of Pd1.3 G/A and Pd1.5 C/T With Risk of Covid-19 in an Iranian Population: A Case-Control Study', Viral Immunology, 35(7), pp. 515-. |
| Vancouver | Damavandi AR, Fathi F, Eskandari N. Response to Sriwijitalai and Wiwanitkit Re: The Association of Programmed Death 1 Gene Polymorphisms of Pd1.3 G/A and Pd1.5 C/T With Risk of Covid-19 in an Iranian Population: A Case-Control Study. Viral Immunology. 2022;35(7):515-. |
| BibTex | @article{ author = {Damavandi AR and Fathi F and Eskandari N}, title = {Response to Sriwijitalai and Wiwanitkit Re: The Association of Programmed Death 1 Gene Polymorphisms of Pd1.3 G/A and Pd1.5 C/T With Risk of Covid-19 in an Iranian Population: A Case-Control Study}, journal = {Viral Immunology}, volume = {35}, number = {7}, pages = {515-}, year = {2022} } |
| RIS | TY - JOUR AU - Damavandi AR AU - Fathi F AU - Eskandari N TI - Response to Sriwijitalai and Wiwanitkit Re: The Association of Programmed Death 1 Gene Polymorphisms of Pd1.3 G/A and Pd1.5 C/T With Risk of Covid-19 in an Iranian Population: A Case-Control Study JO - Viral Immunology VL - 35 IS - 7 SP - 515 EP - PY - 2022 ER - |